WHO Drug Information

Volume 20, 2006 : Index

A

Abetimus, request withdrawn, (4) 273
Access to medicines, developing countries, (3) 191
ACE inhibitors, birth defects, (2) 70
pregnancy, (2) 71
Acetylsalicylic acid, ibuprofen, (3) 188
Adherence to Model List of Essential Medicines,
2-country study, (2) 78
Adverse reaction reporting, (4) 276
Adverse reactions, children, (3) 183
online reporting, (4) 249
African scientists join forces, (4) 266
Analgesic ladder, WHO, (2) 105
Antibiotic use, (1) 31
Antiretroviral price list, (3) 200
programmes, (1) 30
treatment failure, (3) 200
Antiserum supply, (1) 5
Antithrombin alfa, transgenic, (2) 86
Aprotinin, renal toxicity, (1) 16
Artesunate, fake, (3) 193
International Pharmacopoeia monograph, (2) 106
tablets, International Pharmacopoeia monograph,
(2) 107
Article 58, initiative, (1) 19
Asthma/COPD drugs PDD/DDD, (4) 261
ATC synthase inhibitor, (4) 243
ATC/DDD list, final, February 2006, (2) 97
temporary, March 2006, (2) 97
Atomoxetine, suicidality, (1) 9
Avian influenza, WHO guidelines, (2) 104
Benzocaine spray, methaemoglobinaemia, (1) 16
Bevacizumab, lung cancer, (4) 271
Bioglue®, inflammation, (4) 250
Biologicals regulation, world health, (3) 173
Bisimilar product approved, (1) 27
Biphosphonates, osteonecrosis, (3) 181
Boletin farmacos, (1) 30
Bupropion, seasonal depression, (2) 86
Calcitriol, safety, (3) 186
Capecitabine & warfarin, interaction (1) 9
Case safety reports, (1) 26
Cetuximab, cancer, (1) 28
Ciclosporine, safety, (3) 186
Cisplatin, & topotecan cancer, (2) 87
Clarithromycin, safety, (3) 186
Clinical trial registry, WHO, (1) 35
Clopidogrel, (3) 199
Clozapine, monitoring, (1) 10
Colchicine, dosage, (4) 252
toxicity, (1) 17
Compulsory licensing, regulation, (2) 90
Contraception, emergency, (3) 197
Contraceptive skin patch, (2) 69
Corticosteroids, topical, (1) 18
Counterfeit, guidance, pharmacists, (2) 104
medicines, (1) 3
taskforce, WHO, (3) 192
taskforce strategy, (4) 268
Counterfeiting resolution, (3) 193
D
Darifenacin, advantage?, (4) 258
Daunorubicin, safety, (3) 186
Decitabine, myelodysplastic syndromes, (2) 87
Declaration of Rome, counterfeit, (1) 4
Defined and prescribed daily doses, pharmaco-
epidemiology, (4) 261
Development, new TB drugs, (4) 240
Diarylquinolone, (4) 242
Diethylene glycol, Panama, (4) 248
Dipiperdine, (4) 243
Dolasetron, cardiovascular reactions, (3) 185
Dronedarone, withdrawal (3) 199
Drug dependence, Expert Committee recommenda-
tions, (3) 190
Drug-resistant tuberculosis, (4) 239
E
EMEA management board, (2) 86
Emergency health kit, (2) 103
Enoxaparin, kidney disease, (3) 182
Epilepsy drugs, teratogenicity, (4) 246
Ergot derivatives, fibrotic reactions, (1) 15
Essential medicines, children, (3) 191
paediatric, (4) 266
Extensively drug-resistant tuberculosis, (4) 239
Ezetimibe, depression (4) 256
WHO Drug Information Index, Volume 20  2006

F
Flucitasone, safety, (3)  186
Fluoroquinolones, tendon disorders, (1)  15
Fluoroquinolones, warfarin, (1)  9
Fluoxetine, children, (2)  89
safety, (3)  187

G
Gadolinium contrast agents, fibrosis, (2)  71
Galantamine, fatal outcome, (1)  14
Gatifloxacin, blood glucose disturbances, (2)  72
tuberculosis, (1)  11
Global Task Force on XDR-TB, (4)  239
Guidance documents, USA, (4)  280

H
Hepatitis A vaccine, paediatric, (1)  26
HPV vaccine, (2)  88
Hydroxyurea, cutaneous toxicities, (1)  17

I
Ibuprofen, acetylsalicylic acid, (3)  188
ICDRA, International Conference of Drug Regulatory
Authorities, (2)  61
ICH, processes, (4)  267
Innovation & intellectual property, (4)  277
Imatinib, cardiac dysfunction, (4)  248
revised indications, (4)  273
Immune globulin, immune deficiency, (1)  27
haemolysis, (1)  16
Immunization adverse events, monitoring, (3)  180
Immunomodulators, carcinogenic?, (1)  13
IMPACT, counterfeit, (1)  3
Independent drug bulletins, (1)  29
Infectivity, TSE, (2)  91
Infliximab, lymphoma, (3)  181
Influenza virus vaccine, 2006, Northern hemisphere,
(3)  196
2007, Southern hemisphere, (4)  272
InhA inhibitors, (4)  244
Initiative to evaluate developing country medicines,
(1)  19
Innovation, intellectual property rights, public
health (3)  202
Intellectual property rights, innovation, public
health (3)  202
Intellectual property, public hearings, innovation, (4)  277
International Conference of Drug Regulatory
Authorities, ICDRA, (2)  61
International nonproprietary names (INN),
proposed list, 95, (2)  115
proposed list, 96, (4)  281
recommended list, 55, (1)  37
recommended list, 56, (3)  203
Inventory software, (4)  276
Isocitrate lyase inhibitors, (4)  244

K
Ketamine, classified, (1)  28

L
Lamivudine & zidovudine, International Pharmacopoeia
monograph, (2)  112
Lamivudine, oral solution, International Pharmacopoeia
monograph, (2)  107
tablets, International Pharmacopoeia monograph,
(2)  109
Lamotrigine, oral cleft, (3)  181
Leflunomide, neuropathy, (4)  256
Lidocaine-prilocaine, safety, (3)  186
Lothian Formulary, Model List of Essential Medicines,
study, (2)  73

M
Malaria, WHO treatment recommendations, (1)  33
Medical device innovation, (2)  87
Meningococcal vaccine, Guillain Barré, (4)  247
Model List of Essential Medicines, adherence,
2-country study, (2)  78
Model List of Essential Medicines, formulary, study,
(2)  73
Monoclonal antibodies, (3)  165

N
Nanotechnology-based products, (3)  200
Natalizumab, (2)  90
Neonate medicines development, (4)  265
Nimesulide, safety, (3)  187
Nitrofurantoin, lung function, (4)  252
Nitroimidazole, (4)  242-3
NSAIDS, tenofovir, renal failure, (2)  69

O
Oseltamivir, safety update, (4)  257
safety, (1)  11

P
Paediatric, essential medicines, (4)  266
drug information, (1)  31
formulations, resources, (2)  105
Paroxetine, teratogenicity, (1)  12
Patient health & safety, (1)  29
Pegaptanib, hypersensitivity, (1)  16
Pharmaceutical Forum, (4)  278
Pharmaceutical policy analysis, (4)  279
Pharmacoepidemiology, prescribed and defined daily
doses, (4)  261
Pharmacovigilance, Vigiflow online, (4)  275
Pharmacy education, (4)  278
Pipeline, TB drugs, (4)  241
Plant names, (4)  275
Pleuromutillins, (4)  243
Prequalified products, (3) 198
Prescribed and defined daily doses in
pharmacoepidemiology, (4) 261
Prescribing information requirements, (1) 26
Procurement, good governance, (4) 276
Promethazine, children, (1) 12
Propafenone, safety, (3) 187
Proton pump inhibitors, interstitial nephritis, (4) 253
testosterone, (1) 17
Public hearings innovation & intellectual property,
(4) 277
Pyrrole, (4) 243

Q
Quality assurance, guidance, (1) 34
Quality systems, guidance, (4) 279
Quetiapine, urinary disorders, (1) 17

R
Rasagiline, Parkinson disease, (2) 88
Rational medicines management, (1) 31
Rational use of drugs, network, (1) 31
Regulatory pathways, European Union, (1) 19
ReNu Moistureloc® withdrawal, (3) 197
Repaglinide, request withdrawn, (4) 273
Rheumatology guidelines, (2) 103
Risperidone, autism, (4) 271
Ritonavir, safety, (3) 187
Rosiglitazone, diabetic macular oedema, (1) 12

S
Saquinavir, withdrawal, (3) 197
Selegiline, depression (1) 28
Specifications for pharmaceutical preparations, (2) 103
Sirolimus, rejection, (4) 257
Sitagliptin, diabetes, (4) 272
SSRI, newborns, lung disorder, (2) 70
tricyclic antidepressants, interaction, (4) 249
Surfaxin withdrawal, (2) 89

T
TB drug development, (4) 240
Telbivudine, hepatitis B, (4) 271
Telithromycin, hepatic events, (4) 250
Telithromycin, liver toxicity, (1) 14
Tenecteplase, withdrawal, (1) 27
Tenofovir, NSAIDS, renal failure, (2) 69
Terbapenem, blood dyscrasias, (3) 183
Tigecycline, infections, (4) 258
Tipranavir, intracranial haemorrhage, (3) 180
TNF alfa products, hepatitis B, (1) 10
TNF alfa, hepatitis B, (3) 185
Topotecan & cisplatin, cancer, (2) 87
Translocase I inhibitor, (4) 243
Trastuzumab, breast cancer, (196
Treatment, malaria, WHO recommendations, (1) 33
Tricyclic antidepressants, SSRI, interaction, (4) 249
Triple whammy, (4) 251
Tropical disease strategy, (4) 267
TSE, infectivity, (2) 91

U
Unapproved marketed drugs, guide, (2) 104

V
Vaccine, hepatitis A, paediatric, (1) 26
HPV, (2) 88
influenza virus, 2006 Northern hemisphere, (3) 196
influenza virus, 2007 Southern hemisphere , (4) 272
meningococcal, Guillain Barré, (4) 247
Valproic acid, pancreatitis, (3) 185
vCJD infectivity, TSE, (2) 91
Verapamil, safety, (3) 187
Vigiflow online, pharmacovigilance, (4) 275
Vinorelbine, safety, (3) 187

W
Warfarin, capecitabine, interaction (1) 9
Warfarin, fluoroquinolones, (1) 9

Z
Zidovudine & lamivudine, International Pharmacopoeia
monograph, (2) 112